The Role of MPV-to-Lymphocyte Ratio and MPVto- Platelet Ratio in Predicting Mortality in Patients with Acute Myocardial Infarction

The Role of MPV-to-Lymphocyte Ratio and MPVto- Platelet Ratio in Predicting Mortality in Patients with Acute Myocardial Infarction

Objective: In this study, we aimed to evaluate the relationship between the laboratory parameters of mean platelet volume/lymphocyte ratio (MPVLR) and mean platelet volume/platelet ratio (MPVPR) with prognosis and mortality in patients with hospitalized glomerular filtration rate (GFR) <60 and a...

Full description

Saved in:
Bibliographic Details
Published in:Bagcilar Medical Bulletin Vol. 7; no. 1; pp. 32 - 37
Main Authors: Karahan, Serkan, Katkat, Fahrettin, Varol, Sinan, Yıldırım, Mehmet Fırat, İnce, Orhan, Şahin, İrfan, Okuyan, Ertuğrul
Format: Journal Article
Language:English
Turkish
Published: Bagcilar Galenos Publishing House 01-03-2022
Galenos Yayinevi
Subjects:
Acute coronary syndromes
acute myocardial infarction
Blood
Blood platelets
Breast cancer
Cardiovascular disease
Chronic illnesses
Confidence intervals
Coronary vessels
Cytokines
Diabetes
Heart attacks
Hospitalization
Inflammation
Laboratories
Lymphocytes
Mortality
mpv-to-lymphocyte ratio
mpv-to-platelet ratio
Neutrophils
Regression analysis
Risk factors
Vein & artery diseases
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Objective: In this study, we aimed to evaluate the relationship between the laboratory parameters of mean platelet volume/lymphocyte ratio (MPVLR) and mean platelet volume/platelet ratio (MPVPR) with prognosis and mortality in patients with hospitalized glomerular filtration rate (GFR) <60 and a diagnosis of acute myocardial infarction (AMI). Method: This study was designed as a retrospective cohort study. Two hundred myocardial infarction (MI) patients over the age of 18 years and with GFR <60, who were hospitalized in our hospital between January 01, 2018 and January 01, 2021, were included in the study. The patients were divided into 2 groups, as the survivor and mortality groups. The two groups were compared in terms of demographic characteristics and clinical data (symptoms, comorbidities, laboratory findings, GFR, coronary angiography, drugs used and complications). MPVLR was found by dividing the mean platelet volume to lymphocyte count. MPVPR was found by dividing the mean platelet volume to platelet count. Results: The mean age of the survivor group was 64.3±10.4. In the mortality group, the mean age was 70.02±9.3. MPVLR levels were statistically significantly higher in the mortality group (8.39±5.9) compared to the survivor group (6.58±5.4) (p=0.011). However, MPVPR levels were statistically significantly lower in the mortality group (0.041±0.01) compared to the survivor group (0.044±0.01) (p=0.048). According to the results of ROC analysis in patients with mortality, sensitivity was 50.0% and specificity was 68.6% for MPVLR (p=0.010); sensitivity was 41.0% and specificity was 47.9% for MPVPR. The risk factors found to be significantly associated with mortality in the regression analysis included MPVPR [β: 0.045, odds ratio (95% confidence interval): 0.945 (0.899- 1.001), p=0.032]. Conclusion: As inexpensive and easily available new inflammatory markers, MPVLR and MPVPR were significantly higher in patients with GFR <60 and in those who died from AMI. In addition, MPVLR and MPVPR could predict mortality from MI.
ISSN:2547-9431
2547-9431
DOI:10.4274/BMB.galenos.2022.2021-10-112